Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects
Cancer immunotherapy is a therapeutic strategy to inhibit tumor growth and metastasis by intervening in the immune response process. Strategies applied to cancer immunotherapy mainly include blocking immune checkpoints, adoptive transfer of engineered immune cells, cytokine therapy, cancer vaccines,...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-01-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222013877 |
| _version_ | 1811187840176881664 |
|---|---|
| author | Jun Chen Xiufeng Cong |
| author_facet | Jun Chen Xiufeng Cong |
| author_sort | Jun Chen |
| collection | DOAJ |
| description | Cancer immunotherapy is a therapeutic strategy to inhibit tumor growth and metastasis by intervening in the immune response process. Strategies applied to cancer immunotherapy mainly include blocking immune checkpoints, adoptive transfer of engineered immune cells, cytokine therapy, cancer vaccines, and oncolytic virus infection. However, many factors, such as off-target side effects, immunosuppressive cell infiltration and/or upregulation of immune checkpoint expression, cancer cell heterogeneity, and lack of antigen presentation, affect the therapeutic effect of immunotherapy on cancer. To improve the efficacy of targeted immunotherapy and reduce off-target effects, over the past two decades, nanoparticle delivery platforms have been increasingly used in tumor immunotherapy. However, nanoparticles are still subject to biological barriers and biodistribution challenges, which limit their overall clinical potential. This has prompted a series of engineered nanoparticles to overcome specific obstacles and transfer the accumulation of payloads to tumor-infiltrating immune cells. In recent years, new techniques and chemical methods have been employed to modify or functionalize the surfaces of nanoparticles. This review discusses the recent progress of surface-engineered nanoparticles in inducing tumor immune responses and immunotherapy, as well as future directions for the development of next-generation nanomedicines. |
| first_indexed | 2024-04-11T14:10:18Z |
| format | Article |
| id | doaj.art-7094c1c3831c49c49cf62921e2c78f4b |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-11T14:10:18Z |
| publishDate | 2023-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-7094c1c3831c49c49cf62921e2c78f4b2022-12-22T04:19:45ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-01-01157113998Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospectsJun Chen0Xiufeng Cong1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning Province, ChinaCorresponding author.; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110000, Liaoning Province, ChinaCancer immunotherapy is a therapeutic strategy to inhibit tumor growth and metastasis by intervening in the immune response process. Strategies applied to cancer immunotherapy mainly include blocking immune checkpoints, adoptive transfer of engineered immune cells, cytokine therapy, cancer vaccines, and oncolytic virus infection. However, many factors, such as off-target side effects, immunosuppressive cell infiltration and/or upregulation of immune checkpoint expression, cancer cell heterogeneity, and lack of antigen presentation, affect the therapeutic effect of immunotherapy on cancer. To improve the efficacy of targeted immunotherapy and reduce off-target effects, over the past two decades, nanoparticle delivery platforms have been increasingly used in tumor immunotherapy. However, nanoparticles are still subject to biological barriers and biodistribution challenges, which limit their overall clinical potential. This has prompted a series of engineered nanoparticles to overcome specific obstacles and transfer the accumulation of payloads to tumor-infiltrating immune cells. In recent years, new techniques and chemical methods have been employed to modify or functionalize the surfaces of nanoparticles. This review discusses the recent progress of surface-engineered nanoparticles in inducing tumor immune responses and immunotherapy, as well as future directions for the development of next-generation nanomedicines.http://www.sciencedirect.com/science/article/pii/S0753332222013877Surface-engineeredNanoparticlesNanocarriersCancer immune responseCancer immunotherapy |
| spellingShingle | Jun Chen Xiufeng Cong Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects Biomedicine & Pharmacotherapy Surface-engineered Nanoparticles Nanocarriers Cancer immune response Cancer immunotherapy |
| title | Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects |
| title_full | Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects |
| title_fullStr | Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects |
| title_full_unstemmed | Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects |
| title_short | Surface-engineered nanoparticles in cancer immune response and immunotherapy: Current status and future prospects |
| title_sort | surface engineered nanoparticles in cancer immune response and immunotherapy current status and future prospects |
| topic | Surface-engineered Nanoparticles Nanocarriers Cancer immune response Cancer immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S0753332222013877 |
| work_keys_str_mv | AT junchen surfaceengineerednanoparticlesincancerimmuneresponseandimmunotherapycurrentstatusandfutureprospects AT xiufengcong surfaceengineerednanoparticlesincancerimmuneresponseandimmunotherapycurrentstatusandfutureprospects |